The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor.

Virginie Binet, Carole Brajon, Laurent Le Corre, Francine Acher, Jean-Philippe Pin, Laurent Prézeau

To cite this version:

Virginie Binet, Carole Brajon, Laurent Le Corre, Francine Acher, Jean-Philippe Pin, et al.. The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor.. Journal of Biological Chemistry. American Society for Biochemistry and Molecular Biology, 2004, 279 (28), pp.29085-91. <10.1074/jbc.M400930200>. <inserm-00318926>

HAL Id: inserm-00318926
http://www.hal.inserm.fr/inserm-00318926
Submitted on 5 Sep 2008
HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
The heptahelical domain of $\text{GABA}_{B2}$ is directly activated by CGP7930, a positive allosteric modulator of the $\text{GABA}_B$ receptor.

Virginie Binet$^1$, Carole Brajon$^1$, Laurent Le Corre$^2$, Francine Acher$^2$, Jean-Philippe Pin$^1$ and Laurent Prézeau$^1$†

$^1$ Department of Molecular Pharmacology, Laboratory of Functional Genomic, CNRS UPR2580, CCIPE, Montpellier, France.

$^2$ Laboratory of Chemistry and Pharmacological and Toxicological Chemistry, UMR8601-CNRS, University René Descartes-Paris V, Paris, France.

Running title: CGP7930 directly activates the HD of $\text{GABA}_{B2}$

†: To whom correspondence should be addressed:

Laboratory for Functional Genomic, CNRS UPR-2580,
Department of Molecular Pharmacology,
141 rue de la Cardonille,
F-34094 Montpellier Cedex 5, France.
Tel: +33 467 14 2933
Fax: +33 467 54 2432
e.mail: lprezeau@ccipe.cnrs.fr
Number of text pages 21
Number of figures 9
Number of tables 0
Numbers of words in the abstract 286
Numbers of words in the introduction 707
Numbers of words in the discussion 1515

**Key words:** GABA<sub>B</sub> receptor / Allostery / Partial agonist / Dimerization / GPCR / Heptahelical domain / 7TM / Activation mechanism
ABSTRACT

The GABA_B receptor is well recognized as being composed of two subunits, GABA_B1 and GABA_B2. Both subunits share structural homology with other class-III G protein-coupled receptors (GPCRs). They are composed of two main domains, a heptahelical domain (HD) typical of all GPCRs and a large extracellular domain (ECD). Although GABA_B1 binds GABA, GABA_B2 is required for GABA_B1 to reach the cell surface. However, it is still not demonstrated whether the association of these two subunits is always required for function in the brain. Indeed, GABA_B2 plays a major role in the coupling of the heteromer to G proteins, such that it is possible that GABA_B2 can transmit a signal in the absence of GABA_B1. Today only ligands interacting with GABA_B1 ECD have been identified. Thus compounds acting exclusively on the GABA_B2 subunit will be helpful in analyzing the specific role of this subunit in the brain. Here, we explored the mechanism of action of CGP7930, a compound described as a positive allosteric regulator of the GABA_B receptor. We showed that it activates the wild type GABA_B receptor, though with a low efficacy, the GABA_B2 HD being necessary for this effect, although one can not exclude that CGP7930 could also bind to GABA_B1. Of interest, CGP7930 could activate GABA_B2 expressed alone, and is the first described agonist of GABA_B2. Finally, we show that CGP7930 retains its agonist activity on a GABA_B2 subunit deleted of its ECD. This demonstrates the HD of GABA_B2 behaves like a rhodopsin-like receptor, as it can reach the cell surface alone, can couple to G-protein and be activated by agonists. These data open new strategies for studying the mechanism of activation of GABA_B receptor and examine any possible role of homomeric GABA_B2 receptors.
The GABA<sub>B</sub> receptor is a G protein-coupled receptor (GPCR) activated by the most abundant inhibitory neurotransmitter of the central nervous system, γ-amino butyric acid (GABA). This receptor is involved in numerous physiological processes via the regulation of both GABAergic and glutamatergic synapses at either the pre- or post-synaptic level (1). Accordingly, GABA<sub>B</sub> receptors are involved in various types of epilepsy, in nociception and drug addiction, and in spasticity associated with multiple sclerosis (2). Although it has been pharmacologically described for twenty years, only in 1998 was the first GABA<sub>B1</sub> receptor (GABA<sub>B1</sub>) cloned (3). It belonged to the class-III of the GPCR super family, together with the metabotropic glutamate (mGlu), the calcium sensing (CaS), and some pheromone and taste receptors (4). In addition to the typical GPCR heptahelical domain (HD), GABA<sub>B1</sub> possesses a large extracellular domain (ECD), like most other class-III GPCRs (4). In contrast to the rhodopsin-like receptors (class-I GPCRs), the ligand binding site of class-III GPCRs is located within their large ECD, in the so-called Venus Fly-Trap Module (VFTM). Indeed, agonists bind within a cleft that separates the two lobes of the VFTM and stabilize a closed active conformation. This has been recently illustrated by the crystal structures of the mGlu1 ECD that have been solved both in the absence and presence of agonist (5), and confirmed in the case of GABA<sub>B1</sub> by multiple mutagenesis studies (6-8).

However, to form a receptor able to efficiently activate G-proteins, GABA<sub>B1</sub> need to be associated with a homologous protein called GABA<sub>B2</sub> (9-13). GABA<sub>B</sub> receptor was then the first described obligatory heterodimeric receptor. Several studies unraveled some specific roles dedicated to each subunit. First, GABA<sub>B2</sub> takes GABA<sub>B1</sub> to the cell surface probably by masking a retention signal located in GABA<sub>B1</sub> C-terminal tail (14-16). Secondly, GABA<sub>B1</sub> VFTM, but not that of GABA<sub>B2</sub>, binds all known GABA<sub>B</sub> agonists and antagonists, whereas GABA<sub>B2</sub> HD is critical for G protein activation (17-20). Third, there are complex allosteric interactions between the ECD and the HD of both subunits (20-22) leading to optimal agonist affinity and coupling efficacy.

Although the co-expression of both GABA<sub>B1</sub> and GABA<sub>B2</sub> appears to be required for an efficient activation of G-proteins, some studies report a possible functioning of one GABA<sub>B</sub> subunit independently of the other (9) (23). In support of a functional role of GABA<sub>B2</sub> in the absence of GABA<sub>B1</sub>, homodimeric GABA<sub>B2</sub> receptors have been observed at the surface of heterologous cells (24), and homodimeric GABA<sub>B2</sub> HDs are capable of activating G-proteins (20,21). Moreover, localization studies revealed that some neurons in
the brain express much more mRNA of one subunit than of the other consistent with a possible role of homomeric GABA\textsubscript{B} receptors (25). Finally, GABA\textsubscript{B1} may be able to activate intracellular pathways independently of G-proteins (23,26-28). The identification of selective compounds acting on GABA\textsubscript{B2} will probably help unravel this issue.

Within the last few years, allosteric modulators of class-III GPCRs have been identified for CaS and mGlu receptors (29-31). Such compounds act either as non-competitive antagonists (32-34), or as positive allosteric modulators (35-40). In each case, these compounds have been shown to bind within the HD of their targeted receptor (34,41-43). They are also highly selective for one receptor subtype, in contrast to most of the ligand acting at the orthosteric site. Urwyler and coll. recently described the first GABA\textsubscript{B} specific positive allosteric modulators, CGP7930 and CGP13501 and more recently the compound GS39783 (44,45). Their site of action was not identified, but according to what was known for the mGlu specific positive allosteric modulators and to the fact that GABA\textsubscript{B2} coupled to G protein, we hypothesized that these compounds act in the GABA\textsubscript{B2} HD (46).

In the present work, we not only demonstrate that CGP7930 indeed modulates the GABA\textsubscript{B} receptor by directly acting in the GABA\textsubscript{B2} HD, but also that it activates the homomeric GABA\textsubscript{B2} receptor, indicating that GABA\textsubscript{B2} could be functional by itself. Moreover, CGP7930 also activates a truncated version of GABA\textsubscript{B2} deleted of the ECD, demonstrating that this HD can behave like a rhodopsin-like receptor. These data bring much information on the mechanism of action of this GABA\textsubscript{B} positive modulator and reveal that GABA\textsubscript{B2} selective drugs can be identified. Such drugs will be useful to better dissect the specific role of GABA\textsubscript{B1} and GABA\textsubscript{B2} in the brain.
MATERIALS AND METHODS

Materials

Aldehyde CGP13501 was synthetized according to FR2237870 patent and was subsequently reduced with sodium borohydride to afford CGP7930 (mp. 82-84°C, US4333868 patent 86°C).

CGP54626 was purchased from Tocris (Fisher-Bioblock, Illkirch, France). Fetal bovine serum (FBS), culture media and other solutions used for cell culture were from GIBCO-BRL-Life Technologies, Inc. (Cergy Pontoise, France). [3H]-myo-inositol (23.4 Ci/mol) was purchased from Perkin–Elmer Life Science (NEN) (Paris, France). All other reagents used were of molecular or analytical grade where appropriate.

Plasmids and site-directed mutagenesis

The plasmids encoding the wild-type and chimeric GABA\textsubscript{B1a} and GABA\textsubscript{B2} subunits epitope tagged at their N-terminal ends (pRK-GABA\textsubscript{B1a}-HA, pRK-GABA\textsubscript{B1a/2}-HA, pRK-GABA\textsubscript{B2/1}-HA and pRK-GABA\textsubscript{B2}-HA or -cMyc), under the control of a CMV promoter, were previously described (16,20). PRK-HD2 was generated by deletion of the sequence coding for the ECD in the pRK-GABA\textsubscript{B2}-HA plasmid, with the use of the MluI restriction site located just after the sequence coding for the HA tag and a MluI site created just after the proline residues at position 463 in GABA\textsubscript{B2}.

Cell culture and transfection

Human embryonic kidney (HEK) 293 cells were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% FCS and transfected by electroporation as described elsewhere (47,48). Unless stated otherwise, 10.10\textsuperscript{6} cells were transfected with plasmid DNA containing the coding sequence of the receptor subunits, and completed to total amount of 10 µg plasmid DNA with pRK\textsubscript{6}. For determination of inositol phosphate accumulation, the cells were also transfected with the chimeric Goqi9 G-protein which allows the coupling of the recombinant heteromeric GABA\textsubscript{B} receptor to PLC (47).
Measurement of inositol phosphate production

Determination of inositol phosphate (IP) accumulation in transfected cells was performed in 96-wells plates (0.2.10^6 cells/well) after over-night labeling with ^3H-myoinositol (0.5µCi/well) as already described (49). The stimulation was conducted for 30 minutes in a medium containing 10mM LiCl and the indicated concentration of agonist or antagonist. The reaction was stopped with a 0.1M formic acid solution. Supernatants were recovered and IP were purified by ion exchange chromatography using DOWEX AG1-X8 resin (Biorad, Marnes-la-Coquette, France) in 96 well filter plates (ref: MAHVN4550 Millipore, Bedford, MA). Total radioactivity remaining in the membrane fractions was counted after treatment of cells with a solution containing 10% triton X-100 and 0.1N NaOH. Radioactivity was quantified using Wallac 1450 MicroBeta liquid scintillation counter. Data were expressed as IP/Membrane, meaning the amount of total IPs produced over the amount of radioactivity remaining in the membranes, multiplied by 100. Unless stated otherwise, all data are means ± sem of at least 3 independent experiments. The dose-response curves were fitted using the Kaleidagraph program and the following equation "y=[(y_{max} - y_{min})/(1+(x/EC_{50})^{nH})] + y_{min}" where the EC_{50} is the concentration of the compound necessary to obtain 50% of the maximal effect and nH is the Hill coefficient.

Anti-HA ELISA for quantification of cell surface expression

Twenty-four hours after transfection (10.10^6 cells, HA-tagged GABA_{B1} (2µg) and cMyc-tagged GABA_{B2} (2µg) subunits), cells were fixed with 4% paraformaldehyde and then blocked with PBS + 5% FBS. After 30 minutes reaction with primary antibody (monoclonal anti-HA clone 3F10 (Roche, Basel, Switzerland) at 0.5µg/mL) in the same buffer, the goat Anti-Rat antibody coupled to horseradish peroxidase (Jackson Immunoresearch, West Grove, PA) was applied for 30 minutes at 1µg/mL. After intense washes with PBS, secondary antibody was detected and quantified instantaneously by chemiluminescence using Supersignal® ELISA femto maximum sensitivity substrate (Pierce, Rockford, IL) and a Wallac Victor^2 luminescence counter.
GTP-γ-[35S] binding measurements

Cells were transfected using PolyFect transfection reagent (Qiagen, Hilden, Germany) under optimized conditions. Complex were formed using total amount of 8µg plasmid DNA with 60µL of polyfect in 300µL of serum free antibiotic free DMEM for 10 minutes and then added to cells at 40-60% confluence. According expression results, the amount of DNA is GABA_B1 2µg, GABA_B2 1µg, Gα_1c 2µg and pRK_6 3µg for wild-type receptor. Forty-eight hours after transfection, cells were scraped in lysis buffer (15mM Tris, 2mM MgCl_2, 0.3mM EDTA pH 7.4) and centrifuged twice. The pellet was solubilised in Tris (50mM) MgCl_2 (3mM) buffer pH 7.4 using a potter. The GTP-γ-[35S] binding was performed in 96-wells filtration plates (ref: MAFCN0B50, Millipore, Bedford, MA) equilibrated with Tris (50mM) MgCl_2 (5mM) pH7.4. 5µg of membrane preparation per wells were pre-incubated in 20µL with antagonist (15 minutes) and after with agonist (15 minutes). 60µL of incubation buffer (50mM Tris, 1mM EDTA, 10µM GDP, 5mM MgCl_2, 0.01mg/mL leupeptine, 100mM NaCl), and 20µL of H_2O per well were added, and then, the plate was incubated one hour at 30°C. After vacuum filtration and plate filter drying, the radioactivity was measured using a Wallac 1450 MicroBeta liquid scintillation counter. The dose-response curves were fitted using the Kaleidagraph program and the following equation "y=[(y_{max}\cdot y_{min})/(1+(x/EC_{50})^{nH})] +y_{min}" where the EC_{50} is the concentration of the compound necessary to obtain 50% of the maximal effect and nH is the Hill coefficient.
RESULTS

**CGP7930 is a positive allosteric modulator of the GABA<sub>B</sub> receptor**

As previously described by Urwyler et al., CGP7930 increased both the affinity and the maximal effect (about 40%) of GABA in stimulating GTP-γ<sup>[35S]</sup> binding on G<sub>αo</sub>-proteins (Fig.1) (44). Dose-response curves indicate the EC<sub>50</sub> for GABA was increased 3- and 10-fold in the presence of 0.1 and 1mM CGP7930, respectively (42.0 ± 11.0; 30.0 ± 7.5 and 4.7 ± 1.04 µM, in the absence or in the presence of 0.1mM and 1mM CGP7930, respectively). A small increase in the binding of GTP-γ<sup>[35S]</sup> binding was also observed in the absence of GABA, suggesting that CGP7930 may also be able to slightly activate the receptor. However, such an effect of CGP7930 could not be studied in details using this assay according to the high basal GTP-γ<sup>[35S]</sup> binding, and to the low signal to noise ratio of this assay (2 to 3 fold increase observed with a saturating GABA concentration).

Therefore, the effect of CGP7930 was further analyzed using an IP production assay which is supposed to give a higher signal to noise ratio. Indeed the GABA<sub>B</sub> receptor can efficiently activate PLC when co-expressed with the chimeric G-protein Gqi9 (47). As previously noticed, the IP assay is much more sensitive than the GTP-γ<sup>[35S]</sup> assay as indicated by the 100 fold lower EC<sub>50</sub> value measured for GABA compare to the GTP-γ<sup>[35S]</sup> assay. This likely results from the large amplification of the signaling cascade between G-protein activation and IP formation.

As observed with the GTP-γ<sup>[35S]</sup> assay, 100 µM CGP7930 increased GABA potency in stimulating IP formation 3 fold (EC<sub>50</sub>: 0.32 ± 0.10 µM and 0.11 ± 0.02 µM, in the absence and presence of 100 µM CGP7930, respectively), as well as the maximal effect (Fig.2 and 3A). The EC<sub>50</sub> for this effect of CGP7930, as determined by increasing concentrations of this compound in the presence of a fixed concentration of GABA was similar to that determined by Urwyler et al. when using a IP-induced Calcium signal assay (18,9 ± 7,7 and 10 ± 0.1 µM respectively) (44).

However, in this assay, CGP7930 also clearly stimulated IP production even in the absence of added GABA, further suggesting that the CGP7930 could be a GABA<sub>B</sub> partial agonist (Fig.2 and 3).
**CGP7930 is a partial agonist of the GABA<sub>B</sub> receptor**

Additional experiments were performed in order to demonstrate that CGP7930 directly activates the GABA<sub>B</sub> receptor. First, CGP7930 alone did not induce IP formation in pRK6 and Gqi9 transfected control cells, nor in cells co-expressing mGlu5, demonstrating that IP production did not result from a direct action on either the transfected G-protein or PLC (data not shown). Second, the observed stimulation of IP production by CGP7930 (Fig.3A), is dose-dependent with an EC<sub>50</sub> similar to that observed for the potentiating effect (32.5 ± 7.2 µM; Fig.4).

As we could not exclude that the observed effect of CGP7930 was due to overexpression of the receptors, we decided to examine the effect of CGP7930 at different receptor expression levels. To that aim the effect of saturating concentrations of GABA or CGP7930 (1mM) were measured in cells transfected with increasing amount of GABA<sub>B1</sub>- and GABA<sub>B2</sub>-expressing plasmids (Fig.5). The expression levels of heteromeric GABA<sub>B</sub> receptor were determined using ELISA performed on intact cells with an anti-HA antibody labeling the N-terminal HA-tagged GABA<sub>B1</sub> subunit. As shown in Fig.5, the maximal agonist activity of CGP7930 was always lower than the maximal GABA activity, and of course than the maximal activity induced by CGP7930 together with GABA, indicating that CGP7930 was only a partial agonist.

**The heptahelical domain of GB2 is required for the action of CGP7930**

In order to identify the site of action of CGP7930, we first examined whether the stimulatory effect was inhibited by the competitive antagonist CGP54626. As shown in Fig.3B, high concentration of (1 µM, about 250 fold its affinity) totally antagonized the effect of GABA, both compounds binding in the same site in the ECD of GABA<sub>B1</sub>. However, CGP54626 did not completely inhibited (57.5 ± 0.5 % of inhibition) the effect of CGP7930. This suggested that CGP7930 did not bind in the orthosteric site where GABA and competitive antagonists bind within the GABA<sub>B1</sub> ECD, but in another domain, in an allosteric site. Thus, CGP54626 probably allosterically inhibited the CGP7930 effect.

GABA<sub>B</sub> heterodimers can be considered as the association of 4 distinct domains (ECD1, ECD2, HD1 and HD2) that correspond to the ECD and HD of GABA<sub>B1</sub> and GABA<sub>B2</sub> subunits, respectively. To identify which of these domains is required for the effect of CGP7930 its action on various combinations of chimeric and mutated subunits was examined. The chimeric subunits used were GABA<sub>B1/2</sub> and GABA<sub>B2/1</sub>, in which the entire ECD have been swapped between GABA<sub>B1</sub> and GABA<sub>B2</sub> (20).
The \( \text{GABA}_{B1/2} \) was expressed with \( \text{GABA}_{B1} \) to form a receptor that does not contain the ECD2, and vice-versa, \( \text{GABA}_{B2/1} \) was expressed with \( \text{GABA}_{B2} \) to form a receptor devoid of ECD1. Both combinations have already been shown to be expressed at the cell surface and to form heteromeric complexes (20). Although they are not sensitive to GABA, both activate Gq9, as illustrated by the high constitutive IP formation measured in cells expressing these subunit combinations (20). As shown in Fig.6, CGP7930 stimulated IP production in cells expressing either combination (Fig.6, compare lanes 3 and 6). Accordingly, none of the ECD was required for the effect of CGP7930. Then, although we could not rule out that CGP7930 could act similarly on both ECD1 and ECD2 and that only one ECD would be enough for the effect of CGP7930, the more likely possibility was that CGP7930 acts in the HD of either \( \text{GABA}_{B1} \) or \( \text{GABA}_{B2} \).

In order to determine which HD could be the site of action of CGP7930, the effect of CGP7930 was analyzed on the combinations \( \text{GABA}_{B1} + \text{GABA}_{B2/1} \) and \( \text{GABA}_{B2} + \text{GABA}_{B1/2} \). The first combination possessed only HD1 and not HD2, whereas the second possessed HD2 only and not HD1 (Fig.7). In order to allow the correct expression of both \( \text{GABA}_{B1} \) and \( \text{GABA}_{B2/1} \) at the cell surface, the ER retention signal RSR located in the C-terminal tail of these subunits was mutated into ASA (20). Although the combination \( \text{GABA}_{B1} + \text{GABA}_{B2/1} \) was not activated by GABA, whereas the combination \( \text{GABA}_{B2} + \text{GABA}_{B1/2} \) was, both combinations were similarly expressed at the cell surface ((20) and data not shown). As shown in Fig. 7, CGP7930 stimulated the combination containing only HD2 (4 fold increase of the IP production, from 4.7 to 13.8 normalized cpm in the absence and presence of 100µM CGP7930, respectively), but was devoid of activity on that possessing HD1 only. Taken together, these data illustrated the requirement of HD2 for the partial agonist activity of CGP7930 in the \( \text{GABA}_{B} \) heteromer. However, because \( \text{GABA}_{B1} \) cannot activate the G protein by itself, one can not exclude that CGP7930 bound to \( \text{GABA}_{B1} \) but failed at allowing it to stimulate G proteins.

**CGP7930 activated \( \text{GABA}_{B2} \) in the absence of \( \text{GABA}_{B1} \)**

As mentioned above, \( \text{GABA}_{B2} \) possesses sufficient molecular determinants for G-protein activation (17-20). Even when transfected alone, \( \text{GABA}_{B2} \) was highly expressed at the HEK293 cell surface (Fig.8A), allowing us to examine whether CGP7930 could activate this subunit expressed alone. Indeed, whereas GABA is devoid of activity on \( \text{GABA}_{B2} \), CGP7930 increased IP production 3 fold (Fig.8B) with an \( EC_{50} \) of 57.1 ± 3.8 µM (Fig. 9). A similar effect of CGP7930 was observed with the chimeric subunit \( \text{GABA}_{B1/2} \), even though GABA
was inactive (Fig. 8A and B). This confirms that the HD of GABA\textsubscript{B2} is crucial for the CGP7930 effect. However, it is still possible that CGP7930 requires the presence of an ECD, either that of GABA\textsubscript{B1} or GABA\textsubscript{B2}, to turn on the GABA\textsubscript{B2} HD.

**CGP7930 activated GABA\textsubscript{B2} HD (HD2) expressed alone**

According to the data described above, it appeared that CGP7930 could activate GABA\textsubscript{B2} by a direct action in its HD. Thus, we looked for the action of CGP7930 on the HD of GABA\textsubscript{B2} alone. Indeed, we have recently shown that the HD of mGlu5 receptor could be expressed alone and could be directly activated by a positive allosteric modulator of this receptor (49). We therefore generated a truncated version of GABA\textsubscript{B2} lacking the large ECD (Fig. 8). Thanks to the presence of a signal peptide and of a HA tag inserted at the N-terminus, HD2 was found at the cell surface, although at a lower level than the wild-type subunit (30% of the wild type Fig.8A)). On cells expressing HD2, CGP7930 increased IP production more than two folds, with an EC\textsubscript{50} of 64.8 ± 38.7 µM (Fig.9). These data showed that CGP7930 directly stabilizes an active conformation of the GABA\textsubscript{B2} HD, and can be considered as a first GABA\textsubscript{B2} ligand.
DISCUSSION

In the present study, we explored the mechanism of action of CGP7930, one of the first described positive allosteric modulators of the GABA$_B$ receptor (44). Using both GTP-$\gamma$[S] binding and IP production assays, that reflect the activation of G$\alpha$o and G$\alpha$qi9 respectively, we confirmed the positive allosteric action of CGP7930. However, using the more sensitive IP assay – i.e. activation of PLC via G$\alpha$qi9 - CGP7930 was also found to directly activate the GABA$_B$ receptor though with a low efficacy. The action of CGP7930 on various combinations of wild type and chimeric subunits, led us to propose that CGP7930 activated HD2 within the heteromer. This proposal was then directly demonstrated, as we showed that CGP7930 acted as an agonist of HD2 expressed alone, demonstrating this domain of the GABA$_B$ receptor behaved like a rhodopsin-like receptor. It is noteworthy that even if CGP7930 could bind to the HD of GABA$_B$1, it would not induced G protein activation, as we never observed any activation of the recombinant G-proteins by GABA$_B$ receptors lacking HD2 (17,19,20).

CGP7930, a partial agonist of the GABA$_B$ receptor

Not only could CGP7930 potentiate the effect of GABA, as previously reported by others (44), but it could also directly activate the wild-type receptor. This effect occurred in a similar range of concentration as those observed for the potentiating effect, and various arguments excluded the possibility of a potentiation of the effect of a possible endogenous agonist present in the assay medium. Indeed, the effect of CGP7930 was not fully inhibited by a competitive antagonist. Moreover, the effect of CGP7930 could still be observed on various mutated GABA$_B$ receptors not sensitive to GABA.

Since CGP7930 activated GABA$_{B2}$ in the absence of GABA$_{B1}$, then the agonist effect observed could well be the consequence of some GABA$_{B2}$ subunits not associated with GABA$_{B1}$. Although this possibility can not be firmly excluded, we think it is unlikely since we and others observed that in heterologous systems GABA$_{B2}$ was less expressed than GABA$_{B1}$ (8,50). Accordingly, it is very unlikely that there was enough isolated GABA$_{B2}$ subunits (either in a monomeric or homodimeric form) in cells transfected with both GABA$_{B1}$ and GABA$_{B2}$ to generate a CGP7930-induced response higher than that observed in cells expressing GABA$_{B2}$ only.
Of interest, CGP7930 activated not only the heteromeric GABA<sub>B</sub> receptor and the GABA<sub>B2</sub> subunit expressed alone, but also a GABA<sub>B2</sub> subunit deleted of its ECD. Moreover, all these effects were observed in the same range of concentration of CGP7930 (with very similar EC<sub>50</sub> values). This observation clearly indicates that neither GABA<sub>B2</sub> ECD nor the GABA<sub>B1</sub> are required for the agonist activity of CGP7930. Also, this further demonstrates that agonist binding is not required for CGP7930 interaction with HD2.

**On a possible allosteric control of CGP7930 effect**

The affinity of GABA on the ECD of GABA<sub>B1</sub> was allosterically regulated by the other domains of the heteromeric GABA<sub>B</sub> receptor, like the ECD of GABA<sub>B2</sub>. We recently hypothesized that this effect was probably due to the relief by the GABA<sub>B2</sub> ECD of an inhibitory action of the GABA<sub>B1</sub> HD on the GABA<sub>B1</sub> ECD (22). Accordingly, one would expect that the affinity of CGP7930 in the HD of GABA<sub>B2</sub> would also be under the allosteric control of the other domains of the heteromeric complex. The EC<sub>50</sub> of CGP7930 on the wild type receptor, on GABA<sub>B2</sub> or on HD2 were quite similar, whether the agonist effect or the potentiating effect of CGP7930 was measured. This suggests that CGP7930 affinity was not as dependent as GABA affinity on the specific state of the other domains. Alternatively, within this range of concentration tested, CGP7930 may only bind and exert its effect on receptors in a specific state. The identification of radioactive compounds interacting at the same site than CGP7930 would be required to further study this point.

However, the antagonist CGP54626 that likely stabilizes the inactive open state of GABA<sub>B1</sub> ECD, partly inhibited the agonist effect of CGP7930 on the wild-type receptor. Such an effect was not observed on the GABA<sub>B2</sub> subunit expressed alone or on HD2. Then this demonstrated that the action of CGP7930 was dependent of the specific state of the GABA<sub>B1</sub> ECD. To our actual knowledge on the mechanism of activation of the GABA<sub>B</sub> receptor, GABA binding in the VFT of GABA<sub>B1</sub> leads to the closure of the VFT, and to a possible re-orientation of the dimer of VFTs. As a consequence, this stabilizes the active conformation of the dimer of HDs. The competitive antagonist like CGP54626 is expected to prevent the closure of the GABA<sub>B1</sub> VFT, and thus to prevent the stabilization of the active state of the HD dimer by agonists. According to this model, any drug directly stabilizing the dimer of HDs will also stabilize the active conformation of the dimer of VFTs. In agreement with this proposal, CGP7930 increased agonist affinity. Due to allosteric coupling between the dimer of VFTs and the dimer of HD, locking the dimer of VFTs in the inactive state by a competitive antagonist, are expected to make more difficult the change in conformation of the
A model for the action of CGP7930 on the GABA_B receptor

We recently proposed a model for the functioning of class-III GPCRs (56). This model integrated our common view of the functioning of Venus Fly-Trap modules, meaning the binding of the ligand in the cleft between the two lobes of the ECD, and the stabilization of a closed state by agonists, or prevention of the closure of such a domain upon antagonist binding. Moreover, our model takes into account the putative mechanism of activation of the HD, with the existence of at least two states, active and inactive, the equilibrium between these two states being under the control of the specific conformation of the ECD. As discussed in this paper, this model fits very nicely with a series of specific properties of class-III GPCRs. For example, this model provides a reasonable explanation for the lack of inverse agonist activity of competitive antagonists of mGluRs, whereas non-competitive antagonists interacting in the HD were found to be inverse agonists (56).
In this model, we proposed two options to explain the effect of positive allosteric modulators acting in the HD of class-III GPCRs. A first possibility is that such compounds act by stabilizing the active state of the HD, and as a consequence stabilize the active state of the binding domain therefore increasing agonist affinity. According to this proposal, such positive allosteric modulators were expected to also activate with a low efficacy the full-length receptor. This nicely fits with our observation that CGP7930 acted both as an activator and as a positive allosteric modulator of the full-length GABA$_B$ receptor. The second possibility was that the positive modulators acted by increasing the allosteric coupling between the active ECD and the HD, rather than by directly activating the HD. According to the second possibility, the positive modulator directly activated neither the full-length receptor, nor the HD. Our recent observation that the mGlu5 positive modulator, DFB (3,3'-Difluorobenzaldazine), did not activate the full-length receptor, but acted as a full agonist on the receptor deleted of its ECD, did not fit with any of these two possibilities. Accordingly, a more complex model involving 3 states of the mGlu5 HD was proposed (49). This was based on the recognized three states of rhodopsin (57,58) Such an observation provides evidence for a different activation mechanism of GABA$_B$ receptors and the other Class-III GPCRs, such as mGluRs. Indeed, although these two types of receptors share sequence similarities, the GABA$_B$ receptor subunits lack the cystein-rich domain that interconnects the ECD to the HD in the mGlu-like receptors. Further studies will be necessary to better clarify the specific properties of both types of class-III GPCRs.

**Conclusion**

The main observation of this study is that it is possible to identify compounds acting on the GABA$_{B2}$ subunit. As discussed above, such compounds will be useful to elucidate the activation mechanism of such a complex GABA$_B$ heteromeric receptor. In addition, as pointed out in our introduction, it is well recognized that the vast majority of GABA$_{B1}$ and GABA$_{B2}$ subunits associate with each other to form a functional GABA$_B$ receptor in the brain. However, some observations suggest that either GABA$_{B1}$ or GABA$_{B2}$ could be active on their own, or in association with another type of subunit. Our data show that it should be possible to identify compounds acting on GABA$_{B2}$ specifically. Such compounds will help unravel the possible function of this subunit in the brain.
Acknowledgements: The authors wish to thank Drs. Julie Kniazeff, Cyril Goudet, Philippe Rondard, and Thierry Durroux for constructive discussions and critical reading of manuscript. This work was supported by grants from the CNRS, the Action Incitative "Molécules et Cibles Thérapeutiques" from INSERM, CNRS and the French government (J.P.P.), and by Addex Pharmaceuticals (Geneva, Switzerland).
REFERENCES

1. Billinton, A., Ige, A. O., Bolam, J. P., White, J. H., Marshall, F. H., and Emson, P. C. (2001) *Trends Neurosci* **24**, 277-282.
2. Couve, A., Moss, S. J., and Pangalos, M. N. (2000) *Mol Cell Neurosci* **16**, 296-312.
3. Kaupmann, K., Huggel, K., Heid, J., Flor, P. J., Bischoff, S., Mickel, S. J., McMaster, G., Angst, C., Bittiger, H., Froestl, W., and Bettler, B. (1997) *Nature* **386**, 239-246.
4. Pin, J.-P., Galvez, T., and Prezeau, L. (2003) *Pharmacol Ther* **98**, 325-354.
5. Kunishima, N., Shimada, Y., Tsuji, Y., Sato, T., Yamamoto, M., Kumasaka, T., Nakanishi, S., Jingami, H., and Morikawa, K. (2000) *Nature* **407**, 971-977.
6. Galvez, T., Urwyler, S., Prezeau, L., Mosbacher, J., Joly, C., Malitschek, B., Heid, J., Brabet, I., Froestl, W., Bettler, B., Kaupmann, K., and Pin, J. P. (2000) *Mol Pharmacol* **57**, 419-426.
7. Kniazeff, J., Galvez, T., Labesse, G., and Pin, J. P. (2002) *J Neurosci* **22**, 7352-7361.
8. Kniazeff, J., Saintot, P.-P., Goudet, C., Liu, J., Charnet, A., Guillon, G., and Pin, J.-P. (2004) *J. Neuroscience* **24**, 370-377.
9. Kaupmann, K., Malitschek, B., Schuler, V., Heid, J., Froestl, W., Beck, P., Mosbacher, J., Bishoff, S., Kulik, A., Shigemoto, R., Karschin, A., and Bettler, B. (1998) *Nature* **396**, 683-687.
10. Kuner, R., Köhr, G., Grünewald, S., Eisenhardt, G., Bach, A., and Kornau, H.-C. (1999) *Science* **283**, 74-77.
11. Ng, G. Y., Clark, J., Coulombe, N., Ethier, N., Hebert, T. E., Sullivan, R., Kargman, S., Chateauneuf, A., Tsukamoto, N., McDonald, T., Whiting, P., Mezey, E., Johnson, M. P., Liu, Q., Kolakowski, L. F., Jr., Evans, J. F., Bonner, T. I., and O'Neill, G. P. (1999) *J Biol Chem* **274**, 7607-7610.
12. White, J. H., Alan, W., Main, M. J., Green, A., Fraser, N. J., Disney, G. H., Barnes, A. A., Emson, P., Foord, S. M., and Marshall, F. H. (1998) *Nature* **396**, 679-682.
13. Jones, K. A., Borowsky, B., Tamm, J. A., Craig, D. A., Durkin, M. M., Dai, M., Yao, W.-J., Johnson, M., Gunwaldsen, C., Huang, L.-Y., Tang, C., Shen, Q., Salon, J. A., Morse, K., Laz, T., Smith, K. E., Nagarathnam, D., Noble, S. A., Branchek, T. A., and Gerald, C. (1998) *Nature* **396**, 674-679.
14. Calver, A. R., Robbins, M. J., Cosio, C., Rice, S. Q., Babbs, A. J., Hirst, W. D., Boyfield, I., Wood, M. D., Russell, R. B., Price, G. W., Couve, A., Moss, S. J., and Pangalos, M. N. (2001) *J Neurosci* **21**, 1203-1210.
15. Margreta-Mitrovic, M., Jan, Y. N., and Jan, L. Y. (2000) *Neuron* **27**, 97-106.
16. Pagano, A., Rovelli, G., Mosbacher, J., Lohmann, T., Duthey, B., Stauffer, D., Ristig, D., Schuler, V., Heid, J., Meigel, I., Lampert, C., Stein, T., Prézeau, L., Pin, J.-P., Froestl, W., Kuhn, R., Kaupmann, K., and Bettler, B. (2001) *J. Neurosci.* **21**, 1189-1202.
17. Margeta-Mitrovic, M., Jan, Y. N., and Jan, L. Y. (2001) Proc Natl Acad Sci U S A 98, 14649-14654.
18. Duthey, B., Caudron, S., Perroy, J., Bettler, B., Fagni, L., Pin, J. P., and Prezeau, L. (2002) J Biol Chem 277, 3236-3241.
19. Robbins, M. J., Calver, A. R., Filippov, A. K., Hirst, W. D., Russell, R. B., Wood, M. D., Nasir, S., Couve, A., Brown, D. A., Moss, S. J., and Pangalos, M. N. (2001) J Neurosci 21, 8043-8052.
20. Galvez, T., Duthey, B., Kniazeff, J., Blahos, J., Royelli, G., Bettler, B., Prezeau, L., and Pin, J. P. (2001) Embo J 20, 2152-2159.
21. Havlickova, M., Prezeau, L., Bettler, B., Pin, J. P., and Blahos, J. (2001) Mol Pharmacol 62, 343-350.
22. Liu, J., Maurel, D., Etzel, S., Brabet, I., Pin, J.-P., and Rondard, P. (2004) In Press
23. Martin, S. C., Russek, S. J., and Farb, D. H. (1999) Molecular cellular Neurosci. 13, 180-191
24. Maurel, D., Kniazeff, J., Mathis, G., Trinquet, E., Pin, J.-P., and Ansnonay, H. (2004) In Press
25. Calver, A. R., Medhurst, A. D., Robbins, M. J., Charles, K. J., Evans, M. L., Harrison, D. C., Stammers, M., Hughes, S. A., Hervieu, G., Couve, A., Moss, S. J., Middlemiss, D. N., and Pangalos, M. N. (2000) Neuroscience 100, 155-170.
26. Vernon, E., Meyer, G., Pickard, L., Dev, K., Molnar, E., Collingridge, G. L., and Henley, J. M. (2001) Mol Cell Neurosci 17, 637-645.
27. White, J. H., McIlhinney, R. A., Wise, A., Ciruela, F., Chan, W. Y., Emson, P. C., Billinton, A., and Marshall, F. H. (2000) Proc Natl Acad Sci U S A 97, 13967-13972.
28. Nehring, R. B., Horikawa, H. P., El Far, O., Kneussel, M., Brandstatter, J. H., Stamm, S., Wischmeyer, E., Betz, H., and Karschin, A. (2000) J Biol Chem 275, 35185-35191.
29. Pin, J.-P., and Acher, F. (2002) Cur. Drug Targets 1, 297-317
30. Gasparini, F., Kuhn, R., and Pin, J. P. (2002) Curr Opin Pharmacol 2, 43-49.
31. Hu, J., and Spiegel, A. M. (2003) Trends Endocrinol Metab 14, 282-288
32. Carroll, F. Y., Stolle, A., Beart, P. M., Voerste, A., Brabet, I., Mauler, F., Joly, C., Antonicek, H., Bockaert, J., Müller, T., Pin, J. P., and Prézeau, L. (2001) Mol. Pharmacol. 59, 965-973.
33. Litschig, S., Gasparini, F., Rueegg, D., Stoehr, N., Flor, P. J., Vranesic, I., Prezeau, L., Pin, J. P., Thomsen, C., and Kuhn, R. (1999) Mol Pharmacol 55, 453-461.
34. Pagano, A., Rueegg, D., Litschig, S., Stoehr, N., Stierlin, C., Heinrich, M., Floersheim, P., Prezeau, L., Carroll, F., Pin, J. P., Cambria, A., Vranesic, I., Flor, P. J., Gasparini, F., and Kuhn, R. (2000) J Biol Chem 275, 33750-33758.
35. Schaffhauser, H., Rowe, B. A., Morales, S., Chavez-Noriega, L. E., Yin, R., Jachec, C., Rao, S. P., Bain, G., Pinkerton, A. B., Vernier, J. M., Bristow, L. J., Varney, M. A., and Daggett, L. P. (2003) Mol Pharmacol 64, 798-810
36. Johnson, M. P., Baez, M., Jagdmann, G. E., Jr., Britton, T. C., Large, T. H., Callagaro, D. O., Tizzano, J. P., Monn, J. A., and Schoepp, D. D. (2003) J Med Chem 46, 3189-3192
37. Knoflach, F., Mutel, V., Jolidon, S., Kew, J. N., Malherbe, P., Vieira, E., Wichmann, J., and Kemp, J. A. (2001) *Proc Natl Acad Sci U S A* **98**, 13402-13407.
38. Marino, M. J., Williams, D. L., Jr., O’Brien, J. A., Valenti, O., McDonald, T. P., Clements, M. K., Wang, R., DiLella, A. G., Hess, J. F., Kinney, G. G., and Conn, P. J. (2003) *Proc Natl Acad Sci U S A* **100**, 13668-13673.
39. Mathiesen, J. M., Svendsen, N., Brauner-Osborne, H., Thomsen, C., and Ramirez, M. T. (2003) *Br J Pharmacol* **138**, 1026-1030.
40. O’Brien, J. A., Lemaire, W., Chen, T. B., Chang, R. S., Jacobson, M. A., Ha, S. N., Lindsley, C. W., Schaffhauser, H. J., Sur, C., Pettibone, D. J., Conn, P. J., and Williams, D. L., Jr. (2003) *Mol Pharmacol* **64**, 731-740.
41. Malherbe, P., Kratochwil, N., Knoflach, F., Zenner, M. T., Kew, J. N., Kratzeisen, C., Maerki, H. P., Adam, G., and Mutel, V. (2003) *J Biol Chem* **278**, 8340-8347.
42. Malherbe, P., Kratochwil, N., Zenner, M. T., Piussi, J., Diener, C., Kratzeisen, C., Fischer, C., and Porter, R. H. (2003) *Mol Pharmacol* **64**, 823-832.
43. Lavreysen, H., Janssen, C., Bischoff, F., Langlois, X., Leysen, J. E., and Lesage, A. S. (2003) *Mol Pharmacol* **63**, 1082-1093.
44. Urwyler, S., Mosbacher, j., Lingenhoehl, K., Heid, J., Hofstetter, K., Froestl, W., Bettler, B., and Kaupmann, K. (2001) *Mol Pharmacol* **60**, 963-971.
45. Urwyler, S., Pozza, M. F., Lingenhoehl, K., Mosbacher, J., Lampert, C., Froestl, W., Koller, M., and Kaupmann, K. (2003) *J Pharmocol Exp Ther* **307**, 322-330.
46. Pin, J. P., Parmentier, M. L., and Prezeau, L. (2001) *Mol Pharmacol* **60**, 881-884.
47. Franek, M., Pagano, A., Kaupmann, K., Bettler, B., Pin, J. P., and Blahos, J. (1999) *Neuropharmacology* **38**, 1657-1666.
48. Brabet, I., Parmentier, M.-L., Bockaert, J., Acher, F., and Pin, J.-P. (1998) *Neuropharmacology* **37**, 1043-1051.
49. Goudet, C., Gaven, F., Kniazeff, J., Vol, C., Liu, J., Cohen-Gonsaud, M., Acher, F., Prezeau, L., and Pin, J. P. (2004) *Proc Natl Acad Sci U S A* **101**, 378-383.
50. Couve, A., Filippov, A. K., Connolly, C. N., Bettler, B., Brown, D. A., and Moss, S. J. (1998) *J Biol Chem* **273**, 26361-26367.
51. Joly, C., Gomeza, J., Brabet, I., Curry, K., Bockaert, J., and Pin, J.-P. (1995) *J Neurosci.* **15**, 3970-3981.
52. Grunewald, S., Schupp, B. J., Ikeda, S. R., Kuner, R., Steigerwald, F., Kornau, H. C., and Kohr, G. (2002) *Mol Pharmacol* **61**, 1070-1080.
53. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M., and Miyano, M. (2000) *Science* **289**, 739-745.
54. Bouvier, M. (2001) *Nature Rev.* **2**, 274-286.
55. Chabre, M., Cone, R., and Saibil, H. (2003) *Nature* **426**, 30-31; discussion 31.
56. Parmentier, M. L., Prezeau, L., Bockaert, J., and Pin, J. P. (2002) *Trends Pharmacol Sci* **23**, 268-274.
57. Joubert, L., Claeyse, S., Sebben, M., Bessis, A.-S., Clark, R. D., Martin, R. S., Bockaert, J., and Dumuis, A. (2002) *J. Biol. Chem.* **277**, 25502-25511.
58. Okada, T., Enrnst, O., Palczewski, K., and Hofmann, K. P. (2001) Trends Biochem Sci 26, 318-324
LEGENDES

**Figure 1:** Concentration-response curves for GABA on wild type GABA<sub>B</sub> receptor in the absence (■), or in the presence of 100 µM (O) or 1mM (∆) of CGP7930, generated from a GTP-γ[<sup>35</sup>S] binding assay. The GABA EC<sub>50</sub> values determined in the absence, and in the presence of 100 µM or 1mM CGP7930, were 42 µM, 30 µM and 4.7 µM, respectively. The data were expressed as the % of increase of GTP-γ[<sup>35</sup>S] binding above basal. The presented data are from one representative experiment among three experiments performed in triplicate.

**Figure 2:** Concentration-response curves for GABA on wild type GABA<sub>B</sub> receptor, generated from a IP formation assay, in the absence (■), and in the presence of 100 µM of CGP7930 (O). The GABA EC<sub>50</sub> values determined in the absence or in the presence of 100 µM CGP7930 were 0.32 µM and 0.11 µM, respectively. The arrows indicate the EC<sub>50</sub> determined by the curve fits for the conditions without and with CGP7930 respectively. The results are % of the GABA-induced maximal effect on wild type receptor in the absence of CGP7930. The presented data are means of five experiments performed in triplicate.

**Figure 3:** Effect of the CGP7930 (100 µM) and potentiation of the GABA (1 µM) induced-stimulation of IP formation in absence (A) and in presence (B) of 1 µM of the GABA<sub>B</sub> receptor specific competitive antagonist CGP54626. (C) Maximal effects on IP formation obtained with 1 mM of GABA or 1 mM of CGP7930. The presented data are from one representative experiment among three experiments performed in triplicate.

**Figure 4:** Concentration-response curves for CGP7930 generated from the IP formation assay on wild type GABA<sub>B</sub> receptor. The EC<sub>50</sub> value determined for GABA effect was 32.55 ± 7.23
µM. Results are expressed as the % of the CGP7930-induced maximal effect. The presented data are from one representative experiment among eight experiments performed in triplicate.

**Figure 5:** Maximal IP formation response depending of the cell surface receptor expression. IP formation was measured in cells expressing various amounts of the GABA\textsubscript{B} heterodimer without drug (□), or in presence of 1mM of CGP7930 (▲), or of 1mM of GABA (O), or with both drugs (◆). The receptor expression levels are below the level inducing a saturation of the transduction machinery, allowing the observation of the increased maximal response induced by incubation with both compounds, GABA and CGP7930. A.U. stands for Arbitrary Units. The presented data are from one representative experiment among four experiments performed in triplicate.

**Figure 6:** The ECD of GABA\textsubscript{B1} or GABA\textsubscript{B2} are not required for the effect of CGP7930. Effect of the CGP7930 (100 µM) in presence or no of GABA (1 mM) on chimeric receptor formed by the subunit combination GABA\textsubscript{B1} + GABA\textsubscript{B1/2} and GABA\textsubscript{B2} + GABA\textsubscript{B2/1}, in which the ECD of GABA\textsubscript{B2} and that of GABA\textsubscript{B1} is missing respectively. 1 + 1/2 stands for the subunit combinations GABA\textsubscript{B1} + GABA\textsubscript{B1/2}, and 1/2+2 stands for the subunit combination GABA\textsubscript{B2/1} + GABA\textsubscript{B2}. CGP7930 was still able to stimulate the IP formation in cells expressing either combination, indicating that the ECD of GABA\textsubscript{B1} or GABA\textsubscript{B2} subunits are not necessary for the effect of CGP7930. The empty circle represents the ECD of GABA\textsubscript{B1} and the black circle the ECD of GABA\textsubscript{B2}, and the empty square represents the HD of GABA\textsubscript{B1} and the black square the HD of GABA\textsubscript{B2}. The presented data are means of three experiments performed in triplicate.
Figure 7: The HD of GABA$_{B2}$ is required for the effect of CGP7930. The effect of the CGP7930 (100 µM) was examined, in presence or not of GABA (1 mM), on chimeric receptors formed by the subunit combination GABA$_{B1ASA} +$ GABA$_{B2/1ASA}$ and GABA$_{B2} +$ GABA$_{B1/2}$, in which the HD of GABA$_{B2}$ and that of GABA$_{B1}$ is missing respectively. In these combinations, the heterodimeric association of the ECD is conserved, but in contrast, the HD are identical in each combination, displaying then a homomeric HD association. 1ASA+2/1ASA stands for the subunit combinations GABAB$_{1ASA} +$ GABAB$_{2/1ASA}$, and 1/2+2 stands for the subunit combination GABA$_{B1/2} +$ GABA$_{B2}$. The empty circle represents the ECD of GABA$_{B1}$ and the black circle the ECD of GABA$_{B2}$, and the empty square represents the HD of GABA$_{B1}$ and the black square the HD of GABA$_{B2}$. The CGP7930 stimulated only the combination of subunits possessing the HD of GABA$_{B2}$, indicating that the HD of GABA$_{B1}$ was not necessary, in contrast to the HD of GABA$_{B2}$. The presented data are means of three experiments performed in triplicate.

Figure 8: A. Cell surface expression of the wild type GABA$_{B}$ receptor, the GABA$_{B2}$ subunit alone and the HD2 construct. Using the ELISA procedure, the expression of the different proteins was determined for each condition and normalized as a percentage of the wild type GABA$_{B}$ receptor cell surface expression. B. CGP7930 (100 µM) increased the IP production in cells expressing only the HD of GABA$_{B2}$. 2, 1/2, and HD2 stand for GABA$_{B2}$, GABA$_{B1/2}$ and the HD of GABA$_{B2}$ respectively. The empty circle represents the ECD of GABA$_{B1}$ and the black circle the ECD of GABA$_{B2}$, and the black square the HD of GABA$_{B2}$. CGP7930 increased IP formation in cells expressing either the GABA$_{B2}$ subunit alone or the chimeric subunit GABA$_{B1/2}$. Moreover, the HD of GABA$_{B2}$ expressed alone was stimulated by CGP7930, confirming that it is enough for the effect of CGP7930. The presented data are means of four to seven experiments performed in triplicate.
**Figure 9:** Concentration-response curves for CGP7930 generated from the IP formation assay on GABA$_{B2}$ subunit alone (A), and on the HD of GABA$_{B2}$ alone (B). The results are % of the CGP7930-induced maximal effect on each construct. The EC$_{50}$ were 57.1 ± 3.8 and 64.7 ± 38.4 µM in cells expressing GABA$_{B2}$ or the HD of GABA$_{B2}$, respectively. The black circle represents the ECD of GABA$_{B2}$, and the black square the HD of GABA$_{B2}$. The presented data are from representative experiments among four experiments performed in triplicate.
Fig. 1
Fig. 3

(A) GABA - + - +
CGP7930 - - + +

(B) CGP54626

(C) GABA 1mM
CGP7930 1mM
Fig. 6

The diagram shows a bar graph with IP/Membrane values. The x-axis represents different conditions: GABA and CGP7930, while the y-axis represents the values ranging from 0 to 25. Two conditions are compared: 1+1/2 and 2/1+2. The bars indicate the average values with error bars for GABA and CGP7930 treatments.
Fig. 7
Fig. 8
Fig. 9